A phosphate prodrug of a Malt 1 inhibitor

By developing a phosphate prodrug form of MALT1 inhibitor, the problems of insufficient water solubility and bioavailability of existing MALT1 inhibitors have been solved, achieving effective inhibition of the MALT1 signaling pathway and therapeutic effects on related diseases.

CN120418243BActive Publication Date: 2026-11-17JIANGSU HENGRUI MEDICINE CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202380084927.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2022-12-16
Filing Date
2023-12-15
Publication Date
2026-11-17
Estimated Expiration
2043-12-15

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively inhibit the overactivation of the MALT1-NF-κB signaling pathway, which leads to inflammation and tumor development. Furthermore, existing MALT1 inhibitors have limitations in terms of water solubility and bioavailability.

Method used

A class of MALT1 inhibitor phosphate prodrugs has been developed. By converting the compound of formula I into a phosphate prodrug form, its water solubility and bioavailability are improved. Furthermore, by combining it with pharmaceutically acceptable salts, amino acid ester prodrugs, and other forms, its inhibitory activity against MALT1 is enhanced.

Benefits of technology

It significantly improves the water solubility and bioavailability of the compound, enhances its inhibitory activity against MALT1, and provides a more effective drug solution for the treatment of autoimmune diseases, inflammatory diseases, and cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120418243B_ABST
    Figure CN120418243B_ABST
Patent Text Reader

Abstract

This disclosure provides a phosphate prodrug of a Malt1 inhibitor. Specifically, this disclosure provides a prodrug of formula (I) or a pharmaceutically acceptable salt thereof and its use in the preparation of a drug.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Chinese patent application 2022116209806, filed on 2022 / 12 / 16. The entire contents of the aforementioned Chinese patent application are incorporated herein by reference. Technical Field

[0002] This disclosure relates to a compound of Formula I, its preparation method, and its uses, and belongs to the pharmaceutical field. Background Technology

[0003] Mucosa-associated-lymphoid-tissue lymphoma-translocation 1 (MALT1) is an important upstream protein molecule in the NF-κB signaling pathway. It forms the CBM complex with B-cell chronic lymphocytemia / lymphoma 10 (BCL10) and caspase-recruitment domain (CARD) containing membrane-associated guanylate kinase protein 1 (CARMA1), which transmits the proximal antigen receptor protein signal to IκB kinase (IKK), thereby activating the NF-κB signaling pathway. Overactivation of the MALT1-NF-κB signaling pathway is closely related to inflammation and tumorigenesis.

[0004] Patent application PCT / CN2022 / 099499 discloses a class of Malt 1 inhibitors, and the entire contents of patent application PCT / CN2022 / 099499 are incorporated herein by reference. Summary of the Invention

[0005] In a first aspect, this disclosure provides a prodrug of a compound of Formula I or a pharmaceutically acceptable salt thereof.

[0006]

[0007] Secondly, this disclosure also provides a prodrug of a compound as shown in Formula I, wherein the prodrug is selected from a phosphate ester prodrug of a compound of Formula I, a dicarboxylic acid ester prodrug of a compound of Formula I, or an amino acid ester prodrug.

[0008] In some embodiments, the prodrug of the compound represented by Formula I as described in the first aspect may be a phosphate prodrug of the compound of Formula I or a pharmaceutically acceptable salt thereof.

[0009] In some embodiments, the phosphate prodrug of Formula I may have the structure of a compound represented by Formula II-a.

[0010] n is an integer selected from 1 to 5, preferably an integer selected from 1 to 3, and more preferably an integer selected from 1 to 2.

[0011] In some embodiments, the prodrug of the compound represented by Formula I as described in the first aspect may be a dicarboxylic acid ester prodrug of the compound of Formula I.

[0012] In some embodiments, the dicarboxylic acid ester prodrug of Formula I has the structure shown in Formula II-b.

[0013] m is selected from an integer from 1 to 5, preferably from an integer from 1 to 3, and more preferably from an integer from 1 to 2.

[0014] In some embodiments, the prodrug of the compound represented by Formula I as described in the first aspect may be an amino acid ester prodrug of the compound of Formula I, wherein the amino acid may be a common amino acid structure.

[0015] Preferably, the amino acid is a naturally occurring amino acid. More preferably, the amino acid is an α-amino acid. Also preferred is an L-configuration amino acid. The preferred amino acids include twenty essential amino acids. Preferred amino acids are lysine (Lys), leucine (Leu), isoleucine (Ile), glycine (Gly), aspartic acid (Asp), glutamic acid (Glu), methionine (Met), alanine (Ala), valine (Val), proline (Pro), histidine (His), tyrosine (Tyr), serine (Ser), ortholeucine (Nor), arginine (Arg), phenylalanine (Phe), tryptophan (Trp), hydroxyproline (Hyp), homoserine (Hsr), carnitine (Car), ornithine (Ort), canavine (Cav), asparagine (Asn), glutamine (Gln), carnosine (Can), taurine (Tau), S-methylenecysteine ​​(Djk), γ-aminobutyric acid (GABA), cysteine ​​(Cys), cystine (Dcy), sarcosine (Sar), threonine (Thr), and analogues. The preferred amino acids are twenty essential amino acids: Lys, Leu, Ile, Gly, Asp, Glu, Met, Ala, Val, Pro, His, Tyr, Thr, Arg, Phe, Trp, Gln, Asn, Cys, and Ser.

[0016] In some embodiments, the amino acid ester prodrug of Formula I has the structure shown in Formula II-c.

[0017] R is a side group or side chain of an amino acid.

[0018] Thirdly, this disclosure also provides compounds as shown in Formula III or pharmaceutically acceptable salts thereof.

[0019]

[0020] In some embodiments, the compounds or pharmaceutically acceptable salts thereof described in the first, second and third aspects may be selected from inorganic or organic salts, and may also include pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0021] "Pharmaceutically acceptable acid addition salts" refer to salts formed with inorganic or organic acids that retain the bioavailability of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobroms, sulfates, nitrates, and phosphates; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetate, trifluoroacetate, propionates, hexanoates, octanoates, decanoates, undecenoates, glycolates, gluconates, lactates, sebates, adipates, glutarate, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamates, pyroglutamates, aspartates, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginates, ascorbic acid salts, salicylates, 4-aminosalicylic acid salts, and naphthalene disulfonates. These salts can be prepared by methods known in the art.

[0022] "Pharmaceutically acceptable base addition salts" refer to salts formed with inorganic or organic bases that maintain the bioavailability of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Preferred inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts, with sodium salts being the most preferred. Salts derived from organic bases include, but are not limited to, the following: primary amines, secondary amines, and tertiary amines; substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. These salts can be prepared by methods known in the art.

[0023] In some embodiments, the compound or a pharmaceutically acceptable salt thereof, as described in the first, second and third aspects, is used, wherein the pharmaceutically acceptable salt is a sodium salt.

[0024] Fourthly, this disclosure also provides compounds of formula IV or pharmaceutically acceptable salts thereof.

[0025]

[0026] Fifthly, this disclosure provides an isotope-substituted prodrug or its pharmaceutically acceptable salt as described in any of the first to fourth aspects, preferably, the isotope substitution being deuterium atom substitution.

[0027] In a sixth aspect, this disclosure provides a pharmaceutical composition comprising a prodrug as described in any of the first to fourth aspects or a pharmaceutically acceptable salt thereof, or an isotope substitute as described in the fifth aspect, and a pharmaceutically acceptable excipient.

[0028] In some embodiments, the unit dose of the pharmaceutical composition is 0.001 mg to 1000 mg.

[0029] In some embodiments, the pharmaceutical composition contains 0.01-99.99% of the aforementioned compound or a pharmaceutically acceptable salt thereof, based on the total weight of the composition. In some embodiments, the pharmaceutical composition contains 0.1-99.9% of the aforementioned compound or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.5%-99.5% of the aforementioned compound or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 1%-99% of the aforementioned compound or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 2%-98% of the aforementioned compound or a pharmaceutically acceptable salt thereof.

[0030] In some embodiments, the pharmaceutical composition contains 0.01% to 99.99% pharmaceutically acceptable excipients based on the total weight of the composition. In some embodiments, the pharmaceutical composition contains 0.1% to 99.9% pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition contains 0.5% to 99.5% pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition contains 1% to 99% pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition contains 2% to 98% pharmaceutically acceptable excipients.

[0031] This disclosure also provides the use of a prodrug or a pharmaceutically acceptable salt thereof as described in any of the first to fourth aspects, or an isotope substitute as described in the fifth aspect, or a pharmaceutical composition as described in the sixth aspect, in the preparation of a medicament for the prevention and / or treatment of MALT1-related conditions.

[0032] This disclosure also provides a prodrug or a pharmaceutically acceptable salt thereof as described in any of the first to fourth aspects, or an isotope substitute as described in the fifth aspect, or a pharmaceutical composition as described in the sixth aspect, for the prevention and / or treatment of MALT1-related conditions.

[0033] This disclosure also provides the use of a prodrug or a pharmaceutically acceptable salt thereof as described in any of the first to fourth aspects, or an isotope substitute as described in the fifth aspect, or a pharmaceutical composition as described in the sixth aspect, in the preparation of a medicament for the prevention and / or treatment of autoimmune diseases, inflammatory diseases, cancer, or tumors.

[0034] This disclosure also provides a prodrug or a pharmaceutically acceptable salt thereof as described in any one of the first to fourth aspects, or an isotope substitute as described in the fifth aspect, or a pharmaceutical composition as described in the sixth aspect, for the prevention and / or treatment of autoimmune diseases, inflammatory diseases, cancer, and tumors.

[0035] The autoimmune and inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, or vasculitis, and the cancers or tumors, such as primary cancers of the hematopoietic system or solid tumors, including chronic myeloid leukemia, myeloid leukemia, non-Hodgkin's lymphoma, and other B-cell lymphomas.

[0036] This disclosure provides a prodrug of a compound of Formula I or a pharmaceutical salt thereof, wherein the compound of Formula I has good malt1 inhibitory activity and when prepared as a prodrug, its water solubility and pK effect can be significantly improved.

[0037] Terminology Explanation:

[0038] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their physiologically pharmaceutically acceptable salts or prodrugs, along with other chemical components, such as physiologically pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and its biological activity.

[0039] "Pharmaceutical excipients" include, but are not limited to, any adjuvants, carriers, excipients, flow aids, sweeteners, diluents, preservatives, dyes / colorants, flavorings, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, solvents, or emulsifiers that have been approved by the U.S. Food and Drug Administration for use in humans or livestock.

[0040] The term "effective amount" or "effective therapeutic amount" as used in this disclosure includes an amount sufficient to improve or prevent symptoms or conditions of a medical condition. An effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the method, route, and dosage of administration, and the severity of side effects. An effective amount may be the maximum dose or administration regimen that avoids significant side effects or toxicity. Detailed Implementation

[0041] The present invention is further described below with reference to embodiments, but these embodiments are not intended to limit the scope of the present invention.

[0042] Example

[0043] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10⁻¹⁰. -6 The unit (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), with tetramethylsilane (TMS) as the internal standard.

[0044] MS measurements were performed using a Shimadzu 2010 Mass Spectrometer or an Agilent 6110A MSD mass spectrometer.

[0045] High-performance liquid chromatography (HPLC) determinations were performed using Shimadzu LC-20A systems, Shimadzu LC-2010HT series, Shimadzu DGU-20A5R, Shimadzu LC-30AD, Shimadzu SIL-30AC, or an Agilent 1200 LC high-performance liquid chromatograph (Ultimate XB-C18 3.0*150mm column or Xtimate C18 2.1*30mm column).

[0046] Chiral HPLC analysis was performed using Chiralpak IC-3 100×4.6mm ID, 3µm, Chiralpak AD-3 150×4.6mm ID, 3µm, Chiralpak AD-3 50×4.6mm ID, 3µm, Chiralpak AS-3 150×4.6mm ID, 3µm, Chiralpak AS-3 100×4.6mm ID, 3µm, ChiralCel OD-3 150×4.6mm I.D., 3µm, Chiralcel OD-3 100×4.6mm ID, 3µm, ChiralCel OJ-H 150×4.6mm ID, 5µm, and Chiralcel OJ-3 150×4.6mm ID, 3µm columns.

[0047] Thin-layer chromatography silica gel plates are Yantai Huanghai HSGF254 or Qingdao GF254. The silica gel plates used in thin-layer chromatography (TLC) have a diameter of 0.15 mm to 0.2 mm, and the diameter of the silica gel plates used for thin-layer chromatography separation and purification products is 0.4 mm to 0.5 mm.

[0048] Column chromatography typically uses Yantai Huanghai silica gel of 100-200 mesh, 200-300 mesh, or 300-400 mesh as the carrier.

[0049] Chiral preparation columns used were DAICL CHIRALPAK IC (250 mm * 30 mm, 10 μm) or Phenomenex-Amylose-1 (250 mm * 30 mm, 5 μm).

[0050] The CombiFlash rapid preparation system uses a CombiFlash Rf150 (TELEDYNE ISCO).

[0051] Mean inhibition rate of kinases and IC 50 The values ​​were determined using a NovoStar microplate reader (BMG GmbH, Germany).

[0052] The known starting materials of this invention can be synthesized using or according to methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, AccelaChemBio Inc, and Darui Chemicals.

[0053] Unless otherwise specified in the examples, the reactions can be carried out under an argon or nitrogen atmosphere.

[0054] Argon or nitrogen atmosphere refers to a reaction flask connected to an argon or nitrogen gas balloon with a volume of approximately 1L.

[0055] A hydrogen atmosphere refers to a reaction flask connected to a hydrogen balloon with a volume of approximately 1L.

[0056] The pressurized hydrogenation reaction was performed using a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.

[0057] The hydrogenation reaction is usually carried out under vacuum, filled with hydrogen gas, and repeated 3 times.

[0058] The microwave reaction was performed using a CEM Discover-S 908860 microwave reactor.

[0059] Unless otherwise specified in the examples, "solution" refers to an aqueous solution.

[0060] Unless otherwise specified in the examples, the reaction temperature is room temperature, which is 20℃~30℃.

[0061] In the examples, the reaction process was monitored using thin-layer chromatography (TLC). The volume ratio of the developing solvent used in the reaction, the eluent system used for column chromatography to purify the compound, and the developing solvent system for TLC were adjusted according to the polarity of the compound. Generally, water and acetonitrile were used as the mobile phase, but small amounts of basic or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.

[0062] Example 1

[0063] N-(benzo[c][1,2,5]oxadiazol-5-yl)-1-(1-oxo-1,2-dihydroisoquinoline-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide

[0064]

[0065] first step

[0066] 5-Hydroxyisoquinoline 1b

[0067] Isoquinoline-5-amine (5.1 g, 35.37 mmol) was dissolved in concentrated hydrochloric acid (50 mL), and an aqueous solution of sodium nitrite (3.66 g, 53.06 mmol) (20 mL) was added at 0 °C. After reacting for 30 minutes, a concentrated hydrochloric acid solution of stannous chloride (19.95 g, 88.43 mmol) (20 mL) was added dropwise. The reaction was carried out at room temperature for 3 hours. The pH was adjusted to 12–14 with 20% sodium hydroxide aqueous solution, and the mixture was extracted with ethyl acetate (30 mL * 3). The organic phase was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with ethyl acetate elution to give the title compound 1b (2.33 g, yield: 40.0%).

[0068] MS(ESI): m / z = 159.0 [M+H] + .

[0069] Step 2

[0070] 1-(isoquinoline-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester 1d

[0071] 5-Hydroxyisoquinoline (2.33 g, 14.64 mmol) and (Z)-2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutyrate ethyl ester 1c (3.52 g, 14.64 mmol) were dissolved in ethanol (40 mL) and reacted at 60 °C for 3 hours. The crude product was concentrated under reduced pressure and purified by silica gel column chromatography with ethyl acetate elution to give the title compound 1d (2.56 g, yield: 52.1%).

[0072] MS(ESI): m / z = 336.4 [M+H] + .

[0073] Step 3

[0074] 5-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)isoquinoline 2-oxide 1e

[0075] Ethyl 1-(isoquinoline-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (2.56 g, 7.64 mmol) was dissolved in dichloromethane (30 mL), and m-chloroperoxybenzoic acid (3.95 g, 22.9 mmol) was added at 0 °C. The reaction was carried out overnight at room temperature. The mixture was washed successively with semi-saturated sodium bisulfite solution (20 mL x 2) and potassium carbonate solution (20 mL x 2). The organic phase was dried and concentrated under vacuum to give the title compound 1e (2.50 g, yield: 93.21%).

[0076] MS(ESI): m / z = 352.4 [M+H] + .

[0077] Step 4

[0078] 1-(1-Chloroisoquinoline-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester 1f

[0079] 5-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)isoquinoline 2-oxide (2.5 g, 7.12 mmol) was dissolved in chloroform (30 mL), and phosphorus oxychloride (1.33 mL, 14.23 mmol) was added at room temperature. The reaction was carried out at 60 °C for 3 hours, quenched with water (20 mL) in an ice bath, and the organic phase was concentrated under vacuum. The organic phase was purified by silica gel column chromatography by elution with petroleum ether and ethyl acetate to give the title compound 1f (1.96 g, yield: 74.49%).

[0080] MS(ESI): m / z = 370.43 [M+H] + .

[0081] Step 5

[0082] 1g of 1-(1-oxo-1,2-dihydroisoquinoline-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid

[0083] Ethyl 1-(1-chloroisoquinoline-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (1 g, 2.71 mmol) was dissolved in concentrated hydrochloric acid (15 mL), reacted at 120 °C for 3 h, and concentrated under vacuum to give 1 g (864 mg, yield: 98.83%) of the title compound.

[0084] MS(ESI): m / z = 324.4 [M+H] + .

[0085] Step 6

[0086] Benzo[c][1,2,5]oxadiazole-5-amine 1i

[0087] 250 mg (1.25 mmol) of 5-bromobenzo[c][1,2,5]oxadiazole 1h was dissolved in 1.5 mL of ammonia and 1 mL of N-methylpyrrolidone. 36 mg (0.25 mmol) of cuprous oxide was added, and the reaction was carried out in a microwave oven at 140 °C for 1 hour. After the reaction was complete, 10 mL of ethyl acetate was added, followed by washing twice with 10 mL of water and 10 mL of saturated NaCl solution, respectively. The organic phase was concentrated to give the title compound 1i (180 mg, crude product), which did not require further purification and was used directly in the next step.

[0088] MS(ESI) m / z: 136.3 [M+H] + .

[0089] Step 7

[0090] N-(benzo[c][1,2,5]oxadiazol-5-yl)-1-(1-oxo-1,2-dihydroisoquinoline-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide

[0091] Benzo[c][1,2,5]oxadiazole-5-amine 1i (50 mg, 0.37 mmol) was dissolved in pyridine (3 mL), and then 1 g (119 mg, 0.37 mmol) of 1-(1-oxo-1,2-dihydroisoquinoline-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid was added. Phosphorus oxychloride (113 mg, 0.74 mmol) was added at room temperature, and the reaction was carried out at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, purified by C18 reversed-phase column chromatography, and lyophilized to give title compound 1 (8.3 mg, yield: 5%).

[0092] MS(ESI): m / z = 441.6[M+H] + .

[0093] 1 H NMR(400MHz, DMSO-d6)δ11.65(br s, 1H), 11.13 (s, 1H), 8.54 (s, 2H), 8.45 (d, J = 8.0Hz, 1H), 8.13 (d, J = 9.6Hz, 1H), 7.95 (d, J=7.2Hz, 1H), 7.76-7.64 (m, 2H), 7.31 (brs, 1H), 5.67 (d, J=7.6Hz, 1H).

[0094] Example 2

[0095] (5-(4-(benzo[c][1,2,5]oxadiazol-5-ylcarbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-oxoisoquinoline-2(1H)-yl)sodium methylphosphate 2

[0096]

[0097] first step

[0098]

[0099] At room temperature, 2a (148.4 g, 0.337 mol) and paraformaldehyde (151.7 g, 5.06 mol) were suspended in 2000 mL of tetrahydrofuran and heated to 65 °C for 1 to 2 hours. After the reaction was complete, paraformaldehyde was removed by filtration and washed with 6000 mL of tetrahydrofuran. The filtrate was collected, and tetrabenzyl pyrophosphate (236 g, 0.438 mol) was added to it. Argon was used as the replacement gas, and the reaction system was cooled to 0–5 °C. LiHMDS (506 mL, 0.506 mol) was slowly added dropwise to the reaction system. After the addition was complete, the mixture was stirred for 30 minutes. The insoluble matter in the reaction system was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with an eluent system (dichloromethane / methanol = 50 / 1) to give the title product 2b (194.5 g, yield: 79%).

[0100] MS m / z (ESI): 731 [M+1] +

[0101] 1 H NMR (400MHz, d6-DMSO): δ11.11 (s, 1H), 8.56 (d, 1H, J = 10.8Hz), 8.51 (d, 1H, J = 8.0Hz), 8.14 (d, 1H, J = 9.6Hz), 8.03 (d, 1H, J = 7.6Hz) , 7.78-7.72 (m, 2H), 7.62 (d, 1H, J=7.6Hz), 7.32 (s, 10H), 5.91 (dd, 2H, J=9.6, 4.8Hz), 5.81 (d, 1H, J=8.0Hz), 5.06 (d, 4H, J=8.0Hz).

[0102] Step 2

[0103]

[0104] Add 2b (193 g, 0.264 mol), 10% Pd / C (19.3 g), and 1500 mL of tetrahydrofuran to the reaction flask, replacing the gas in the flask with argon. Stir at room temperature until the reactants are completely converted. After the reaction is complete, filter with diatomaceous earth to remove Pd / C, wash Pd / C with tetrahydrofuran while keeping it moist. Collect the filtrate and concentrate under reduced pressure. After concentrating to dryness, add 1000 mL of methanol, filter to remove a small amount of insoluble impurities, and wash with 500 mL of methanol. Dissolve NaOH (18.9 g, 0.472 mol) in 70 mL of purified water and slowly add it dropwise to the methanol solution under ice bath conditions. After the addition is complete, concentrate the methanol solution to dryness under reduced pressure, reconstitute with water, and purify by reversed-phase column chromatography (packing material: C18, mobile phase: 10% methanol, 90% water, isocratic elution). Concentrate the prepared solution, freeze-dry, and obtain title compound 2 (86 g, yield: 54.7%).

[0105] MS m / z (ESI): 551 [M+1] +

[0106] 1 H NMR (400MHz, D2O): δ8.44 (d, 1H, J=8.0Hz), 8.24 (s, 1H), 8.04 (s, 1H), 7.84 (d, 1H, J=7.6Hz), 7.76 (d, 1H, J=9.6Hz), 7. 63 (t, 1H, J = 8.0Hz), 7.56 (d, 1H, J = 7.6Hz), 7.41 (d, 1H, J = 9.6Hz), 6.10 (d, 1H, J = 7.6Hz), 5.59 (dd, 1H, J = 17.4, 6.2Hz).

[0107] Test Example 1: MALT1 Biochemical Protease Assay

[0108] MALT1 protease activity was assessed in vitro using a tetrapeptide (Ac-LRSR-MCA, PEPTIDE INSTITUTE) as a substrate and full-length MALT1 protein (Strep-MALT1(1-824)-Myc / DDK, ORIGENE TP314639) purified from mammalian HEK293T cells. The tetrapeptide LRSR is conjugated to AMC (7-amino-4-methylcoumarin) and provides a fluorescent substrate for quenching the MALT1 protease. Cleavage of AMC at arginine residues resulted in an increase in coumarin fluorescence measured at 450 nm (excitation at 360 nm). The final assay buffer consisted of 5.625 nM MALT1 protein, 2.5 μM Ac-LRSR-MCA, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl·6H2O, 1 mM 2Na (EDTA·2Na), 0.01% Triton X-100, 1 M trisodium citrate dihydrate, and 10 mM DTT. The test compounds dissolved in 100% DMSO were added to each well of a 384-well plate (Greiner-781086) using an Echo. The maximum concentration of each test compound was 10 μM or 1 μM, with 3-fold serial dilutions, ranging from 10 μM to 0.2 nM. Control wells containing the enzyme-free assay buffer served as low controls (LC), while wells containing the enzyme-reacted but untreated solvent (1% DMSO) served as high controls (HC). The compound was incubated with the MALT1 enzyme and substrate at room temperature for 15 hours. Fluorescence was then measured at excitation 360 nm and emission 450 nm using Envision. Inhibition curves were fitted using XLfit, and IC50 was calculated. 50 Value, IC 50 The values ​​are shown in Table 1.

[0109] Calculate IC using the following formula 50 Value (Z prime > 0.5):

[0110] LC = Median of low control value

[0111] Low control: Response without MALT1 enzyme

[0112] HC = Median of high control value

[0113] High control: Solvent control without compounds

[0114] Inhibition % = 100 - [(sample-LC) / (HC-LC)×100]

[0115] Curve fitting formula: fit=(A+((BA) / (1+((C / x)^D))))

[0116] A: Min(Bottom), B: Max(Top), C: IC 50 (Inflection point), D: Slope (Hill value)

[0117] Table 1

[0118]

[0119] Experimental results: The IC50 of compound 1 disclosed herein inhibits the MALT1 biochemical protease. 50 With a value of 34 nM, it exhibits good inhibitory activity.

[0120] Test Example 2: Determination of Compound Solubility

[0121] 1. Preparation method of buffer solution and physiological media

[0122] (1) Preparation method of FaSSIF solution:

[0123] Preparation method of fasting-simulated intestinal fluid (FaSSIF):

[0124] Step 1: Dissolve 0.420g sodium hydroxide, 4.470g disodium hydrogen phosphate, and 6.186g sodium chloride in 900mL of purified water. Adjust the pH to 6.50 with 1N sodium hydroxide solution or 1N HCl, and dilute to 1000mL with purified water at room temperature. Shake well.

[0125] Step 2: Add 2.240g of FaSSIF / FeSSIF / FaSSGF powder (brand: Biorelevant) to 500mL of the above buffer solution, stir until the powder is completely dissolved, and then add buffer solution to make up the volume to 1000mL at room temperature.

[0126] (2) Preparation of buffer solutions with different pH values:

[0127] Hydrochloric acid solution with pH 1.0: Take 0.9 mL of concentrated hydrochloric acid, add it to 100 mL of ultrapure water, and shake well to obtain a hydrochloric acid solution with pH 1.0.

[0128] pH 3.0-8.0 Phosphate Buffer: Weigh 14.2732g of disodium hydrogen phosphate and add water to 500mL to obtain a 200mM disodium hydrogen phosphate aqueous solution. Shake well to dissolve and use as solution A. Weigh 4.2145g of citric acid monohydrate and add water to 200mL. Shake well to obtain solution B. Take different volumes of solution A and solution B respectively to obtain phosphate buffer solutions with pH 3.0, 4.0, 5.0, 6.0, 6.8, 7.4 and 8.0.

[0129] 2. Determination of equilibrium solubility

[0130] The equilibrium solubility of compounds 1 and 2 was determined using the standard shake-flask method.

[0131] 3 Experimental Results

[0132]

[0133] Conclusion: Compound 2 showed significantly improved water solubility compared to compound 1 in different pH values ​​and simulated biological media.

[0134] Test Example 3: Pharmacokinetic Evaluation of Compounds 1 and 2

[0135] Using SD rats as test animals, the plasma concentration of compound 1 at different time points after gavage administration of compound 1 and compound 2 was determined by LC / MS / MS. The pharmacokinetic behavior of the disclosed compounds in rats was investigated to evaluate their pharmacokinetic characteristics.

[0136] 1. Test Protocol

[0137] 1.1 Preparation of test sample

[0138] Accurately weigh appropriate amounts of compound 1 and compound 2, add an appropriate volume of 0.5% MC (methylcellulose), and vortex sonicate to mix thoroughly to prepare the required drug formulation for oral administration by gavage.

[0139] 1.2 Experimental Animals

[0140] SD rats, SPF grade, transferred from the experimental animal reserve (999M-017) of the Experimental Animal Management Department of Shanghai Institute of Family Planning Science, 4 females.

[0141] 1.3 Administration method

[0142] Weigh the patient before administration and calculate the dosage based on their body weight. Administer orally via gavage.

[0143] 1.4 Blood Collection Time Points

[0144] 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, and 24h after administration.

[0145] 1.5 Sample Collection and Processing

[0146] Blood was collected via the jugular vein, with approximately 200 μL collected per sample. The samples were anticoagulated with EDTA-K2 and placed on ice. Plasma was separated by centrifugation within one hour (centrifugation conditions: 6800 g, 6 minutes, 2-8°C). Collected plasma samples were stored at -70°C before analysis, and any remaining plasma samples after analysis were also stored at -70°C for one month.

[0147] 2. Bioanalysis and Data Processing

[0148] The concentration of compound 1 in plasma samples was detected, and semi-quantitative analysis of metabolites with known ion-pair mass-to-charge ratio information was performed. The accuracy of quality control samples was evaluated simultaneously with the sample analysis, and more than 66% of the quality control samples were required to have an accuracy between 80-120%.

[0149] When plotting plasma drug concentration-time curves, BLQ is recorded as 0. When calculating pharmacokinetic parameters, the concentration before administration is calculated as 0; BLQ before Cmax (including "No peak") is calculated as 0; BLQ after Cmax (including "No peak") is not included in the calculation.

[0150] Pharmacokinetic parameters such as AUC(0-t), T1 / 2, Cmax, Tmax, and MRT were calculated using blood drug concentration data at different time points using WinNonlin.

[0151] 3 Experimental Results

[0152] The pharmacokinetic parameters of the disclosed compound are as follows:

[0153]

[0154]

[0155] Conclusion: The pharmacokinetic properties of compound 2 (the phosphate prodrug of compound 1) are compared with those of compound 1.

[0156] AUC last / D It increased by 3.8 times (10360.06 vs 2147.60), demonstrating a significant pharmacokinetic advantage.

Claims

1. The compound shown in formula II-a or its pharmaceutically acceptable salt, , n is an integer selected from 1 to 5.

2. The compound or its pharmaceutically acceptable salt according to claim 1, wherein n is selected from an integer from 1 to 3.

3. The compound or its pharmaceutically acceptable salt according to claim 1, wherein it is 。 4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable salt is a sodium salt.

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein it is 。 6. The compound according to any one of claims 1-5, or an isotope-substituted product of the pharmaceutically acceptable salt thereof, wherein the isotope substitution is deuterium substitution.

7. A pharmaceutical composition comprising the compound according to any one of claims 1-5 or a pharmaceutically acceptable salt thereof or an isotope substitute according to claim 6 and a pharmaceutically acceptable excipient.

8. Use of the compound of any one of claims 1-5 or a pharmaceutically acceptable salt thereof, or an isotope substitute of claim 6, or a pharmaceutical composition of claim 7, in the preparation of a medicament for the prevention and / or treatment of MALT1-related conditions.

9. The use according to claim 8, characterized in that, MALT1-related conditions are selected from autoimmune diseases, inflammatory diseases, and tumors.

Citation Information

Patent Citations

  • Malt1 inhibitor, and preparation method therefor and use thereof

    WO2022262855A1